IPA Raises $50,000 For the Juvenille Diabetes Research Foundation

IPA hosted its 3rd annual charity golf event at The Seven Bridges Golf Course on August 27, 2005 and raised $50,000 for the Juvenile Diabetes Research Foundation (JDRF).

"The IPA golf outing was a tremendous success raising $50,000 for diabetes research," said Amy Franze, Executive Director for JDRF. "It is because of companies like IPA that we will find a cure."

In addition to the donation made to JDRF, participating golfers won donated prizes of gift certificates, golf accessories and hotel packages. The day began with a continental breakfast, golf clinic and pitch and putt contest. A 19th Hole Party, Million Dollar Shootout, auction and dinner followed the outing. All proceeds benefited JDRF.

"This event allowed our sponsors, professional athletes and the employees of IPA and our family of companies the opportunity to participate in raising money for Juvenile Diabetes research," said Gregg M. Steinberg, president of IPA. "I am hopeful that we have in a small way moved up the time table to finding a cure."

Founded by parents of children with juvenile diabetes, the Juvenile Diabetes Research Foundation (JDRF) has always focused on a single goal—accelerating research progress to cure diabetes and its complications. The research management process is unique and organized as a diabetes cure enterprise. JDRF takes informed risks, continuously monitors the global diabetes research landscape and makes investments strategically to ensure that resources are effectively directed to research with the greatest impact leading to a cure as soon as possible. This dedication has led to spending more money for diabetes research than any other charitable organization—more than $800 million since its founding in 1970, including more than $85 million in FY 2004 alone. More than 80 percent of JDRF’s expenditures directly support research and research-related education. In FY 2004, JDRF funded 500 centers, grants and fellowships in 19 countries. In addition, the advocacy has spurred the government to increase its investment in type 1 diabetes research to unprecedented levels.